Background
Phase III, open-label RCT (AHL2011, LYSA). 823 patients with newly diagnosed advanced-stage classical Hodgkin lymphoma (stage III–IV or stage IIB with bulky or extranodal disease). Tested whether PET-adapted treatment de-escalation (switching from BEACOPP escalated to ABVD in early PET2-negative responders) maintains efficacy while reducing toxicity compared to standard BEACOPP escalated throughout.
Interventions and follow up
Arm A (standard): BEACOPP escalated × 6 cycles in advanced-stage HL
Arm B (PET-driven): BEACOPP escalated × 2, then ABVD × 4 if PET2-negative (de-escalation), continuing BEACOPP escalated if PET2-positive
Primary endpoint: 5-year PFS non-inferiority of PET-driven de-escalation vs standard BEACOPP escalated
Median follow up: 50.4 months
Arm B (PET-driven): BEACOPP escalated × 2, then ABVD × 4 if PET2-negative (de-escalation), continuing BEACOPP escalated if PET2-positive
Primary endpoint: 5-year PFS non-inferiority of PET-driven de-escalation vs standard BEACOPP escalated
Median follow up: 50.4 months
Results
5-year PFS (ITT): 85.7% (PET-driven) vs 86.2% (standard) — non-inferiority demonstrated (HR 1.084, 95% CI 0.737–1.596)
5-year PFS (PET2-negative, de-escalated): 86.7%
5-year OS: 95.2% vs 96.7% — no significant difference
PET2-negative rate: 87.0% of patients de-escalated to ABVD
5-year PFS (PET2-negative, de-escalated): 86.7%
5-year OS: 95.2% vs 96.7% — no significant difference
PET2-negative rate: 87.0% of patients de-escalated to ABVD
Adverse events
Hematologic: PET-driven arm less grade ≥3 neutropenia (67% vs 80%); febrile neutropenia 22% vs 32%
Infection/late: Grade ≥3 infections 11% vs 17%; secondary AML/MDS lower numerically in de-escalated arm
Infection/late: Grade ≥3 infections 11% vs 17%; secondary AML/MDS lower numerically in de-escalated arm
Conclusions
PET-adapted de-escalation (2×BEACOPP escalated → ABVD in PET2-negative patients) maintains 5-year PFS equivalent to 6×BEACOPP escalated with significantly reduced acute toxicity, validating early PET-response-adapted treatment as a standard approach in advanced cHL.
Key Limitations
The de-escalation strategy still requires upfront BEACOPP escalated × 2, retaining its acute toxicity in all patients. PET2-positive patients (~13%) continuing intensive therapy had worse outcomes, identifying a high-risk subset not addressed by this design. The trial predates brentuximab-based (ECHELON-1) and BrECADD (HD21) regimens now reshaping advanced cHL. Generalizability to non-GHSG/non-LYSA centers and to North American ABVD-based practice is limited.
Clinical Context
AHL2011 supports a PET-adapted de-escalation strategy for advanced cHL in centers using BEACOPP escalated, reducing exposure to its toxicity in early responders. ESMO recognizes PET-response-adapted approaches; ASCO-aligned North American practice more commonly uses ABVD/A+AVD (ECHELON-1) frontline. HD18 (4×eBEACOPP for PET-negative) and HD21 (BrECADD) have since further refined GHSG advanced-stage management.